Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VNRX 
Volitionrx Ltd (VNRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VNRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -30.27% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.99M USD | Price to earnings Ratio - | 1Y Target Price 3.37 |
Price to earnings Ratio - | 1Y Target Price 3.37 | ||
Volume (30-day avg) 130966 | Beta 1.1 | 52 Weeks Range 0.43 - 1.02 | Updated Date 04/1/2025 |
52 Weeks Range 0.43 - 1.02 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -0.0533 | Actual -0.06 |
Profitability
Profit Margin - | Operating Margin (TTM) -1236.76% |
Management Effectiveness
Return on Assets (TTM) -122% | Return on Equity (TTM) -730.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 52164044 | Price to Sales(TTM) 42.55 |
Enterprise Value 52164044 | Price to Sales(TTM) 42.55 | ||
Enterprise Value to Revenue 41.42 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 98331504 | Shares Floating 62740564 |
Shares Outstanding 98331504 | Shares Floating 62740564 | ||
Percent Insiders 22.83 | Percent Institutions 19.37 |
Analyst Ratings
Rating 4.33 | Target Price 3.34 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Volitionrx Ltd
Company Overview
History and Background
VolitionRx Ltd. is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Founded in 2010, the company focuses on Nucleosomicsu2122, which examines nucleosomes, the fundamental building blocks of chromosomes, for disease-related information.
Core Business Areas
- Diagnostics Development: VolitionRx focuses on developing and commercializing blood-based diagnostic tests, primarily for cancer detection and monitoring, based on its Nucleosomicsu2122 technology platform. These tests aim to provide early and accurate detection to improve patient outcomes.
Leadership and Structure
Cameron Reynolds serves as the Chief Executive Officer. The company has a board of directors overseeing the strategic direction and corporate governance.
Top Products and Market Share
Key Offerings
- Nu.Qu00ae: Nu.Qu00ae is VolitionRx's primary technology platform for developing cancer diagnostic tests. It focuses on identifying and quantifying nucleosomes in blood samples to detect cancer signals. Market share data specific to Nu.Qu00ae tests are not widely available, as the company is still in the process of commercializing these products. Competitors include companies developing liquid biopsy technologies, such as Guardant Health (GH) and Exact Sciences (EXAS).
Market Dynamics
Industry Overview
The cancer diagnostics market is experiencing substantial growth, driven by an increasing incidence of cancer globally and a growing demand for non-invasive and early detection methods. Liquid biopsy, the focus of VolitionRx, is a rapidly evolving segment within this market.
Positioning
VolitionRx is positioned as a developer of innovative, blood-based cancer diagnostics using its proprietary Nucleosomicsu2122 technology. Its competitive advantage lies in its unique approach to analyzing nucleosomes for cancer detection.
Total Addressable Market (TAM)
The global cancer diagnostics market is estimated to be hundreds of billions of dollars. VolitionRx is positioned to capture a share of the liquid biopsy segment, offering potential for significant growth if they can successfully commercialize their products.
Upturn SWOT Analysis
Strengths
- Proprietary Nucleosomicsu2122 technology
- Potential for early cancer detection
- Non-invasive blood-based tests
- Strong intellectual property portfolio
Weaknesses
- Limited commercialization to date
- High cash burn rate
- Reliance on clinical trial results
- Regulatory hurdles
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new cancer types
- Increasing demand for liquid biopsy
- Geographic expansion
Threats
- Competition from established players
- Failure to achieve regulatory approvals
- Technological advancements by competitors
- Lack of market adoption
Competitors and Market Share
Key Competitors
- GH
- EXAS
- TMO
Competitive Landscape
VolitionRx faces intense competition from larger, more established companies in the cancer diagnostics market. Its success depends on demonstrating the clinical utility and cost-effectiveness of its Nu.Qu00ae technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on research and development.
Future Projections: Future projections depend on successful commercialization of Nu.Qu00ae tests.
Recent Initiatives: Recent initiatives include ongoing clinical trials, partnerships with research institutions, and regulatory submissions.
Summary
VolitionRx is an epigenetics company with innovative technology for cancer diagnostics. The company faces significant challenges related to commercialization and competition. Successful clinical trials and regulatory approvals are critical for its future success. VolitionRx needs to secure partnerships and funding to support its growth strategy. It should look out for funding issues.
Similar Companies
EXAS
EXACT Sciences Corporation
EXAS
EXACT Sciences Corporation
GH
Guardant Health Inc
GH
Guardant Health Inc
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- VolitionRx Ltd. company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. The analysis is based on publicly available information and may be subject to change. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Volitionrx Ltd
Exchange NYSE MKT | Headquaters Henderson, NV, United States | ||
IPO Launch date 2007-04-25 | Founder, CEO, President & Director Mr. Cameron Reynolds MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 96 | Website https://www.volition.com |
Full time employees 96 | Website https://www.volition.com | ||
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.